Our Pricing

Ozempic vs Mounjaro UK: Complete Clinical Comparison

Comparing ozempic vs mounjaro uk price and efficacy? Both are GLP-1 receptor agonists licensed by the MHRA for weight management, but they differ significantly in mechanism, dosing schedules, and clinical outcomes. At Cured Pharmacy, we offer transparent upfront pricing with Mounjaro available from £135.00 alongside comprehensive alternatives including Wegovy and Saxenda, all requiring assessment by our UK-registered prescribers.

Ozempic vs Mounjaro UK: Key Differences Explained

Mounjaro (tirzepatide) and Ozempic (semaglutide) both belong to the incretin mimetic class, but Mounjaro represents a significant pharmacological advancement as the first dual GIP/GLP-1 receptor agonist licensed in the UK [1]. While Ozempic activates only GLP-1 receptors to regulate appetite and blood glucose, Mounjaro simultaneously targets both GIP and GLP-1 pathways, producing enhanced metabolic effects.

In head-to-head clinical trials, tirzepatide demonstrated superior weight reduction compared to semaglutide. The SURPASS-2 trial showed patients on Mounjaro 15mg achieved an average 12.4kg greater weight loss than those on semaglutide 1mg over 40 weeks [1]. This dual-action mechanism appears to provide stronger appetite suppression and improved insulin sensitivity, though individual responses vary based on metabolic factors and adherence.

Both medications require once-weekly subcutaneous injection and gradual dose escalation to minimise gastrointestinal side effects. Ozempic is typically initiated at 0.25mg weekly, whilst Mounjaro begins at 2.5mg weekly, with both treatments titrated upward based on tolerance and clinical response [2].

Mounjaro Dosing Schedule: 2.5mg to 15mg Explained

Mounjaro is available in five dose strengths in the UK: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. The standard titration protocol begins with 2.5mg once weekly for four weeks, allowing your body to adapt to the medication's effects on gastric emptying and appetite regulation [1].

After the initial month, your prescriber will typically increase your dose to 5mg weekly, with subsequent 2.5mg increments every four weeks until reaching your maintenance dose. Clinical trials demonstrated that higher doses produced greater weight reduction, with the 15mg dose achieving an average 22.5% body weight reduction over 72 weeks in the SURPASS-3 trial [3]. However, not all patients require or tolerate the maximum dose—your UK prescriber will determine the optimal dose based on your response and any side effects experienced.

Each KwikPen contains four single-dose injections, meaning one pen provides a month's supply at any given dose strength. Cured Pharmacy stocks all Mounjaro doses from 2.5mg through 15mg, ensuring continuity throughout your treatment journey without supply interruptions.

Dose Escalation and Clinical Monitoring

Gradual dose escalation is essential for tolerability. Approximately 20-30% of patients in clinical trials experienced nausea during the first weeks of treatment, but this typically diminished with continued use [1]. Your prescriber may recommend remaining at a lower dose if you achieve satisfactory weight loss or experience persistent gastrointestinal symptoms. Regular monitoring through follow-up consultations ensures your treatment remains safe and effective throughout the titration process.

Clinical Efficacy: Weight Loss Results from SURPASS and STEP Trials

The SURPASS clinical trial programme evaluated tirzepatide across multiple studies involving over 6,000 participants. In SURPASS-1, patients receiving Mounjaro 15mg achieved an average weight reduction of 11.0kg compared to 0.9kg with placebo over 40 weeks—a statistically significant difference that exceeded initial projections [3].

Comparatively, the STEP trials examining semaglutide (the active ingredient in Ozempic and Wegovy) demonstrated average weight loss of 14.9% from baseline with semaglutide 2.4mg over 68 weeks [4]. Whilst both medications produce clinically meaningful weight reduction, tirzepatide's dual-receptor mechanism appears to offer enhanced efficacy in direct comparison studies, though individual responses vary considerably based on baseline BMI, adherence, and lifestyle modifications.

It's crucial to understand that these are average results from controlled clinical trials. Real-world outcomes depend on multiple factors including dietary adherence, physical activity levels, baseline metabolic health, and consistent medication use. Neither medication works without concurrent lifestyle changes—they are pharmacological tools that reduce appetite and improve satiety, making calorie restriction more achievable [2][4].

Long-Term Weight Maintenance Considerations

Clinical data suggests that weight regain commonly occurs after discontinuation of GLP-1 receptor agonists. The STEP-1 trial extension showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide [4]. This highlights the importance of viewing these medications as long-term management tools rather than short-term solutions, combined with sustainable dietary and behavioural changes to optimise lasting results.

Side Effects and Safety Profile: What UK Patients Should Know

Both Mounjaro and Ozempic share similar side effect profiles due to their GLP-1 receptor activity. The most commonly reported adverse effects are gastrointestinal: nausea (affecting 20-40% of patients initially), diarrhoea, constipation, vomiting, and abdominal discomfort [1][3]. These symptoms typically emerge during dose escalation and diminish over 4-8 weeks as your body adapts to delayed gastric emptying.

More serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when combined with other glucose-lowering medications). The MHRA advises patients to seek immediate medical attention if experiencing severe persistent abdominal pain, as this may indicate pancreatitis [2]. Additionally, both medications carry warnings regarding thyroid C-cell tumours based on rodent studies, though no causal relationship has been established in humans.

Contraindications include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these conditions during your clinical assessment. Pregnant or breastfeeding women should not use either medication, and both should be discontinued at least two months before planned conception due to unknown foetal effects [1][2].

Ozempic vs Mounjaro UK Price and Availability at Cured Pharmacy

Mounjaro is available at Cured Pharmacy with transparent upfront pricing, ensuring you know costs before completing your free clinical consultation. Our pricing structure reflects competitive UK market rates whilst maintaining the highest standards of pharmaceutical care and regulatory compliance.

Unlike Ozempic, which is not currently licensed for weight management in the UK (though it contains the same active ingredient as Wegovy), Mounjaro holds specific MHRA authorisation for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities [2]. This distinction is important for prescription legality and insurance considerations.

All doses from 2.5mg through 15mg are available through our online consultation service, completed in under three minutes by UK-registered prescribers. Following approval, your medication is dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and delivered in discreet packaging directly to your address. We guarantee genuine UK-licensed medicines—every Mounjaro pen supplied carries full MHRA authorisation and batch traceability.

Prescription Requirements and Clinical Assessment

Both Mounjaro and Ozempic are prescription-only medicines in the UK, requiring clinical assessment by a registered prescriber before dispensing. Our online consultation evaluates your medical history, current medications, weight management goals, and any contraindications. The assessment takes approximately three minutes and is reviewed by a UK prescriber typically within hours during working days. If approved, your prescription is issued electronically to our pharmacy for immediate dispensing and dispatch.

Alternative Weight Loss Treatments Available at Cured Pharmacy

Beyond Mounjaro, Cured Pharmacy offers a comprehensive range of MHRA-licensed weight management treatments to suit different clinical needs and budgets. Wegovy (semaglutide 2.4mg) provides an established GLP-1 option with extensive clinical evidence, whilst Saxenda (liraglutide) offers a daily injection alternative for patients who prefer more frequent but lower-dose administration.

For patients seeking non-injectable options, we stock Orlistat (generic and branded as Xenical), which works through a different mechanism by blocking approximately 30% of dietary fat absorption in the intestines [5]. Orlistat may be suitable for individuals uncomfortable with injections or those with contraindications to GLP-1 receptor agonists. Additionally, we offer Alli (lower-dose orlistat) and Orlos for over-the-counter weight management support.

Your prescriber will discuss which treatment aligns best with your medical profile, lifestyle preferences, and weight loss objectives during your consultation. Some patients transition between treatments based on efficacy, tolerability, or cost considerations—our clinical team provides ongoing support throughout your weight management journey, with regular reviews to optimise outcomes and address any emerging concerns.

Combination Approaches and Lifestyle Integration

NICE guidelines emphasise that pharmacological interventions should complement—not replace—dietary modification, increased physical activity, and behavioural strategies [6]. Our prescribers can provide guidance on evidence-based lifestyle changes that maximise medication efficacy, including structured meal planning, portion control techniques, and sustainable exercise programmes tailored to your current fitness level. The most successful outcomes occur when medication reduces appetite barriers whilst you simultaneously establish healthier long-term habits.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside pharmacological treatment.